|
|
|
|
|
Pergolide
drug data and news
Pergolide drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Pergolide | ||
| Brand Names/Synonyms | PERGOLIDE; Pergolida [Inn-Spanish]; Pergolide; Pergolide Mesylate; Pergolide Methanesulfonate; Pergolidum [Inn-Latin]; Permax | ||
| Indication | Indicated as adjunctive treatment to levodopa/carbidopa in the management of the signs and symptoms of Parkinson’s disease. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Pergolide is an ergot derivative dopamine receptor agonist at both D1 and D2 receptor sites. Pergolide is 10 to 1,000 times more potent than bromocriptine on a milligram per milligram basis in various in vitro and in vivo test systems. Pergolide mesylate inhibits the secretion of prolactin in humans; it causes a transient rise in serum concentrations of growth hormone and a decrease in serum concentrations of luteinizing hormone. In Parkinson’s disease, pergolide mesylate is believed to exert its therapeutic effect by directly stimulating postsynaptic dopamine receptors in the nigrostriatal system. | ||
| Mechanism Of Action | Pergolide is a potent dopamine receptor agonist. It directly stimulates post-synaptic dopamine receptors at both D1 and D2 receptor sites in the nigrostriatal system. | ||
| Pergolide News (When available) |
Pensioner given 20 times required medication May 4, 2006 Parkinson Disease Guidelines Aid Diagnosis, Management May 9, 2006 | ||
| Dosage Forms | TABLET | ||
| Drug_Category | Neuroprotective Agents; Antiparkinson Agents; Antidyskinetics; Dopamine Agonists; Central Nervous System Agents; ATC:N04BC02 | ||
| Absorption | Significant amount may be absorbed (evidence on bioavailability still lacking). | ||
| Interactions |
Interactions for Pergolide: Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); these agents may diminish the effectiveness of Permax. Because pergolide mesylate is approximately 90% bound to plasma proteins, caution should be exercised if pergolide mesylate is coadministered with other drugs known to affect protein binding. | ||
| Toxicity | Oral, rat LD50: 15 mg/kg. Symptoms of overdose include nausea, vomiting, convulsions, decreased blood pressure, and CNS stimulation. | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | Not Available | ||
| Chemical Formula | C19H26N2S | ||
| Molecular Weight | 314.489 g/mol | ||
| Smiles String | CCCN1CC(CC2C1CC3=CNC4=CC=CC2=C34)CSC | ||
| Melting Point | 207.5 °C | ||
| Water Solubility | Not Available | ||
| State | Solid | ||
| LogP/Hphobicity | 4.02 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Not Available | ||
| Half Life | Not Available | ||
| Protein Binding [%] | 90% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Pergolide.html http://www.rxlist.com/cgi/generic2/pergol.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00663 | ||
| CAS Registry Number | 66104-22-1 | ||
| KEGG Compound ID | C07425 | ||
| PubChem ID | SID:9629 | ||
| PharmGKB ID | PA450873 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2123320 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |